Topic: Ambien
Investment View. . I believe that Transcept's (TSPT) Intermezzo is an important new drug for insomnia and will be a commercial success. I am...
Transcept Pharmaceuticals, Inc. (TSPT) awaits a major Federal Drug Administration (FDA) New Drug Application (NDA) decision on November 27th. The...
View the image larger here Travel voyeurs, every last one of us! It's time for a new series wherein you show off what you're working with. That is...
For some people, getting a little shuteye isn't a simple matter of, well, shutting their eyes. Some have trouble falling asleep, some wake up in...
FDA rejections are almost always painful for biotechnology companies, and Tuesday's press release from Transcept Pharmaceuticals (Nasdaq:TSPT)...
With the euphoria that is ASCO 2011 rapidly fading in the rear view mirror, biotech investors are eyeing the road ahead in search of catalysts and...
Quick thing: I was thinking about my unbelievable hatred of transcon redeye flights (I can't sleep because you can't take Ambien on a 4 hour flight...
I know how everyone loves trip reports. Here, I'll throw you a bone: January 9: Newark - Copenhagen SAS A330, Business Class I'll be honest: I took...
On January 10, 2011 we sat down with Glenn Oclassen, CEO and Tom Soloway, CFO, for an update on the current business plans at Transcept...
WASHINGTON (Reuters) - The popular sleep drug Ambien can leave even the healthiest older people groggy and prone to stumbling, falling and confusion when they wake up, U.S. researchers reported on Thursday.The drug, sold by Sanofi Aventis under the brand name ...
